Nikhil Gupte, PhD

CRS:

BJMC

Role:

Regulatory and Data ManagementResearch Staff

Position:

CRS Data Manager and Deputy Director

Nikhil Gupte, PhD, is a Research Associate faculty member at the Johns Hopkins School of Medicine and Deputy Director of the Byramjee Jeejeebhoy Government Medical College (BJGMC)-JHU Clinical Trials Unit (CTU), a collaborative research partnership associated with the world’s largest HIV therapeutic trials networks, the AIDS Clinial Trials Group [ACTG] and the International Maternal Pediatric and Adolescent AIDS Clinical Trial Network (IMPAACT).

Dr. Gupte has more than 10 years of experience in public health research in developing countries and is a recognized leader in biostatistics education in India. Based in Pune, India, Dr. Gupte is the lead statistician for the BJGMC-JHU CTU, which conducts Phase I, II and III clinical trials of therapeutic drug interventions for HIV and co-morbid infections, such as tuberculosis and hepatitis, in adults (including pregnant women) and children. An experienced educator, Dr. Gupte has developed and taught biostatistics courses in India, including a number of University courses and NIH-supported training courses, and he currently leads the Biostatistics training for the BJGMC-JHU Fogarty HIV-TB Training Program.

A recipient of the Hopkins Fogarty fellowship, Dr. Gupte received a Doctor of Philosophy in Biostatistics from the Johns Hopkins Bloomberg School of Public Health.

  • Member, Site Operations Subcommittee
  • NWCS 319, parent study A5175
  • NWCS 408, parent study A5274
  • NWCS 414, parent study A5274

.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More